Welcome to the Boehringer Ingelheim Pharmaceuticals Inc.(BIPI) and Lilly USA, LLC (Lilly) Alliance on-line application and grant management portal.

      On January 11, 2011 BIPI and Lilly announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. We are committed to supporting education that fosters innovative, high quality, independent medical education for healthcare professionals and patients that narrows unmet medical needs, maintains clinical excellence, and measurably improves health outcomes in areas of interest to the BIPI and Lilly Diabetes Alliance.

      By agreement between BIPI and Lilly, grant requests will be processed through the BIPI on-line grant system but the application request will be reviewed by both companies. Please review the following prior to submitting a request through our on-line system.

      Medical Education Grants

      A BIPI/Lilly medical education grant is designed to support independent medical education for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health.

      Please see below for submission timelines:

      • Grant applications must be submitted no less than 60 days prior to the program start date.

      New and Returning Visitors to BIPI/Lilly Medical Grants

      To begin a new application, return to a saved application, or track the status of an application already submitted login at https://funding.boehringer-ingelheim.com/welcome/US/. If this is the first time you are visiting the site, you must register as a New User. An application ID beginning with "US IME", will be assigned once you submit the application.

      Educational Objectives - Cardiometabolism

      1. Improve clinicians’ understanding of the unmet medical needs, clinical practice guidelines, and scientific evidence while managing the cardiovascular and/or renal risk in patients with Type 2 diabetes.
      2. Improve clinicians’ understanding of the unmet medical needs, clinical practice guidelines, and scientific evidence regarding treatment of patients with one or more of the following: Type 2 diabetes, Heart Failure (including pEF and rEF), and Chronic Kidney Disease.
      3. Improve clinician’s understanding of emerging clinical information on the course of disease, clinical impact and management of T2D patients, with or without cardiovascular and/or renal disease/risk, who have contracted COVID-19.

      Important please note: Any grant applications that have a focus on insulins will not be considered by the BI Lilly Alliance through the BIPI Grant Funding System. For any new grant applications focused on insulins, please reach out to the Lilly Grant Office, https://www.lillygrantoffice.com/

      Responding to a Request for Proposal (RFP)
      Throughout the year, the Medical Grants department may announce a Request for Proposal (RFP). The intent of this announcement is to notify experienced and accredited Continuing Medical Education (CME) providers and accredited Continuing Education (CE) providers that BIPI/Lilly is interested in receiving applications for educational grants for support consideration.

      Grant applications in response to BIPI/Lilly Alliance RFPs need to be submitted online at https://funding.boehringer-ingelheim.com/welcome/US/. While RFPs may specify timing of requested responses, BIPI and Lilly will continue to review all grant requests which are received.

      To contact the BIPI/Lilly Alliance Medical Grants Department, please send an email to MEDSCICOMMOps.US@boehringer-ingelheim.com.